Ortiz et al. (2018) stated that cardiometabolic risk may be associated with increased DNA methylation of FKBP5, which is associated with the risk factors for CAD, such as the higher levels of glycosylated hemoglobin, low-density lipoprotein cholesterol, body mass index, and waist circumference. Moreover, FKBP5 increases platelet expression in patients with myocardial infarction, which mostly occurs because of CAD (Eicher et al., 2016). Here, FKBP5 is linked to myocardial infarction.